SHPG : Summary for Shire plc - Yahoo Finance

U.S. Markets close in 1 hr 54 mins

Shire plc (SHPG)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
180.48-0.60 (-0.33%)
As of 2:05PM EST. Market open.
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close181.08
Bid180.30 x 200
Ask180.36 x 100
Day's Range179.40 - 181.98
52 Week Range161.09 - 209.22
Avg. Volume1,072,177
Market Cap53.39B
PE Ratio (TTM)275.96
Earnings DateN/A
Dividend & Yield0.80 (0.44%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters3 hours ago

    Bristol-Myers adds 3 directors in agreement with JANA Partners

    Drugmaker Bristol-Myers Squibb Co said on Tuesday it appointed three directors to its board in an agreement with JANA Partners LLC, an activist investor holding less than 1 percent of the company's stock. The move comes as Bristol-Myers has fallen behind Merck & Co Inc after its immunotherapy Opdivo failed as an initial treatment for non-small cell lung cancer, the largest oncology market. Bristol-Myers also announced a $2 billion accelerated share repurchase program.

  • Shire Plc :SHPG-US: Earnings Analysis: Q4, 2016 By the Numbers : February 21, 2017
    Capital Cube5 hours ago

    Shire Plc :SHPG-US: Earnings Analysis: Q4, 2016 By the Numbers : February 21, 2017

    Categories: Yahoo Finance Get free summary analysis Shire Plc reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of Shire Plc – Pfizer Inc., Johnson & Johnson, Eisai Co., Ltd. Sponsored ADR, Sanofi Sponsored ADR, Teva Pharmaceutical Industries Limited Sponsored ADR and GlaxoSmithKline plc Sponsored ADR (PFE-US, JNJ-US, ... Read more (Read more...)

  • Financial Times14 hours ago

    [$$] Big pharma bets billions on 'silent' liver disease

    Big pharma thinks it has spotted its next big opportunity - an untreatable silent killer that affects millions of people. In recent months, large drugmakers including Allergan, Gilead and Novartis have ...